Insider Selling: 10x Genomics, Inc. (NASDAQ:TXG) Insider Sells 17,000 Shares of Stock


Share on StockTwits

10x Genomics, Inc. (NASDAQ:TXG) insider Bradford Crutchfield sold 17,000 shares of the firm’s stock in a transaction that occurred on Monday, April 12th. The shares were sold at an average price of $185.89, for a total value of $3,160,130.00. Following the completion of the transaction, the insider now owns 51,608 shares in the company, valued at approximately $9,593,411.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

TXG stock opened at $196.13 on Friday. The business has a fifty day moving average of $174.22 and a two-hundred day moving average of $161.05. The stock has a market cap of $21.33 billion, a price-to-earnings ratio of -145.28 and a beta of 1.39. 10x Genomics, Inc. has a 52-week low of $66.26 and a 52-week high of $203.20.

10x Genomics (NASDAQ:TXG) last posted its earnings results on Tuesday, February 16th. The company reported ($3.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($3.59). The business had revenue of $112.22 million for the quarter, compared to analyst estimates of $101.20 million. 10x Genomics had a negative return on equity of 19.98% and a negative net margin of 51.27%. As a group, analysts predict that 10x Genomics, Inc. will post -1.18 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of the business. Advisory Services Network LLC acquired a new stake in 10x Genomics during the fourth quarter worth $30,000. HM Payson & Co. purchased a new position in shares of 10x Genomics during the third quarter worth $27,000. GSA Capital Partners LLP boosted its position in shares of 10x Genomics by 14.4% during the fourth quarter. GSA Capital Partners LLP now owns 1,888 shares of the company’s stock worth $267,000 after buying an additional 238 shares during the period. IBM Retirement Fund boosted its position in shares of 10x Genomics by 14.9% during the fourth quarter. IBM Retirement Fund now owns 2,126 shares of the company’s stock worth $301,000 after buying an additional 275 shares during the period. Finally, Strs Ohio boosted its position in shares of 10x Genomics by 5.0% during the fourth quarter. Strs Ohio now owns 6,636 shares of the company’s stock worth $939,000 after buying an additional 316 shares during the period. 68.84% of the stock is owned by institutional investors.

Several equities analysts have recently weighed in on TXG shares. William Blair started coverage on 10x Genomics in a research report on Monday, March 22nd. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. increased their price target on 10x Genomics from $160.00 to $195.00 and gave the company an “overweight” rating in a report on Thursday, February 25th. Citigroup increased their price target on 10x Genomics from $195.00 to $240.00 and gave the company a “buy” rating in a report on Thursday, February 25th. Cowen increased their price target on 10x Genomics from $155.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, February 25th. Finally, Morgan Stanley increased their price target on 10x Genomics from $145.00 to $215.00 and gave the company an “overweight” rating in a report on Thursday, February 25th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $183.70.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.

Featured Article: Lock-Up Period Expiration

Insider Buying and Selling by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.